✦ LIBER ✦

Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia

✍ Scribed by S. Kageyama; M. Masuya; I. Tanaka; K. Oka; K. Morita; S. Tamaki; K. Tsuji; N. Katayama; H. Sugimoto; Y. Kagawa; M. Kojima; H. Shiku

Publisher: Springer
Year: 1999
Tongue: English
Weight: 53 KB
Volume: 5
Category: Article
ISSN: 1341-321X
DOI: 10.1007/s101560050038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of intravenous voric

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Gloria N. Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Ko 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 139 KB

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA

Plasma levels of IL-1, TNF alpha, IL-6,

Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia

✍ H. Schönbohn; M. Schuler; K. Kolbe; C. Peschel; C. Huber; W. Bemb; W. E. Aulitzk 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 806 KB